PROJECT TEAM
Line Vigga Kristensen, Cand. Public Health
Kristian Stærk, MD, Postdoc in the Research Unit of Clinical Microbiology, Odense University Hospital
THE NEED
Urinary tract infections affect over 400 million people worldwide annually and account for 15% of global antibiotic use. Current diagnostic tools, like dipstick tests, have low accuracy, leading to misdiagnosis, delayed treatment, and antibiotic overprescription. These issues impact vulnerable populations such as the elderly, infants, and those with comorbidities, increasing morbidity, mortality, and healthcare costs.
THE SOLUTION
Uvigga integrates lateral flow assay technology with NGAL and IL6 biomarkers to detect UTIs more accurately and faster than standard urine cultures or dipstick tests. The test is user-friendly, cost-effective, and delivers reliable point-of-care results. It reduces diagnostic uncertainty, enabling timely and targeted treatment while lowering the risk of unnecessary antibiotic use and hospital admissions.
Detection of UTI - Odense University Hospital
Call 5 - 2024
500.000 DKK
Clinical Area
Urology
Technology
BioTech
PROJECT SUMMARY
Uvigga is a lateral flow assay test designed for accurate, early point-of-care diagnosis of urinary tract infections (UTIs). By combining traditional markers with innovative biomarkers, it aims to reduce misdiagnosis, antibiotic overuse, and improve treatment outcomes.
CLINICAL IMPACT
By improving UTI detection and reducing diagnostic errors, Uvigga can lead to faster recovery, fewer complications, and a significant reduction in antibiotic misuse. This enhances patient safety and quality of care while decreasing healthcare costs. The solution is especially impactful for high-risk patient groups, ensuring earlier and more precise interventions.